Hematology TimesTrials of atezolizumab placed on partial holdSeptember 19, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFDA approves drug to treat relapsed FLSeptember 15, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesImmune status linked to outcomes of CAR T-cell therapySeptember 15, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersALLNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsBiosimilar matches rituximab in large follicular lymphoma trialSeptember 12, 2017Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesBiosimilar deemed equivalent to reference drug in FLSeptember 12, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsFDA grants Priority Review to Gazyva for follicular lymphomaAugust 29, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesDrug receives priority review for FLAugust 29, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Oncology PracticeObinutuzumab-CHOP not superior to rituximab-CHOP in new DLBCLAugust 17, 2017Lymphoma & Plasma Cell DisordersAggressive LymphomasFollicular Lymphoma
Hematology TimesAnalysis reveals poor outcomes in refractory DLBCLAugust 12, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesCHMP recommends new indication for obinutuzumabJuly 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsIMiD/Anti-CD20 combo induces complete responses in r/r NHLJuly 19, 2017Mantle Cell LymphomaLymphoma & Plasma Cell DisordersAggressive LymphomasImmuno-oncologyFollicular Lymphoma
Hematology NewsCopanlisib makes inroads against relapsed/refractory follicular lymphomaJuly 11, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesCombo demonstrates activity in CLL/SLL and FLJuly 11, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsTazemetostat active against follicular lymphoma with EZH2 mutationJuly 7, 2017Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesCAR T-cell therapy shows early promise in DLBCLJune 30, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
